Answers are grounded in this paper and cite their sources.
The paper presents the resolution of the VII Annual Scientific and Practical Conference with International Participation “Real Clinical Practice. Possible and Real” (Moscow, September 24, 2026), organized by leading professional associations. The document summarizes discussions on the implementation of real-world data and real-world evidence (RWD/RWE) in Russia and the EAEU. It systematizes regulatory and legal barriers in medicinal product regulation, health technology assessment, clinical guideline development, innovative drug provision models, healthcare information systems and registries, and personal data protection and processing. Proposals are formulated to improve legislation, including clarification of the concepts of de-identification and anonymization, broader access to de-identified data, consideration of RWD/RWE in comprehensive drug assessment and list formation, development of interoperability and health data exchange standards (HL7 FHIR), and harmonization at the EAEU level. The resolution also highlights interagency and expert collaboration and the involvement of patient communities.
No takes yet. Share an insight, caveat, or question.
Колбин et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: